JP2018520124A - Ｎｕｔ正中線癌の治療 - Google Patents

Ｎｕｔ正中線癌の治療 Download PDF

Info

Publication number
JP2018520124A
JP2018520124A JP2017563973A JP2017563973A JP2018520124A JP 2018520124 A JP2018520124 A JP 2018520124A JP 2017563973 A JP2017563973 A JP 2017563973A JP 2017563973 A JP2017563973 A JP 2017563973A JP 2018520124 A JP2018520124 A JP 2018520124A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
cycloalkyl
substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017563973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520124A5 (enExample
Inventor
ランドー，スティーブン，ビー．
ケーギー，マイケル，エイチ．
Original Assignee
テンシャ セラピューティクス，インコーポレイテッド
テンシャ セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テンシャ セラピューティクス，インコーポレイテッド, テンシャ セラピューティクス，インコーポレイテッド filed Critical テンシャ セラピューティクス，インコーポレイテッド
Publication of JP2018520124A publication Critical patent/JP2018520124A/ja
Publication of JP2018520124A5 publication Critical patent/JP2018520124A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/57557—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017563973A 2015-06-26 2016-06-24 Ｎｕｔ正中線癌の治療 Pending JP2018520124A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
US62/185,203 2015-06-26
PCT/US2016/039270 WO2016210275A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Publications (2)

Publication Number Publication Date
JP2018520124A true JP2018520124A (ja) 2018-07-26
JP2018520124A5 JP2018520124A5 (enExample) 2019-07-25

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017563973A Pending JP2018520124A (ja) 2015-06-26 2016-06-24 Ｎｕｔ正中線癌の治療

Country Status (14)

Country Link
US (1) US20180193350A1 (enExample)
EP (1) EP3314005A1 (enExample)
JP (1) JP2018520124A (enExample)
KR (1) KR20180035785A (enExample)
CN (1) CN107787227A (enExample)
AR (1) AR105124A1 (enExample)
AU (1) AU2016283020A1 (enExample)
BR (1) BR112017028178A2 (enExample)
CA (1) CA2989313A1 (enExample)
HK (1) HK1252062A1 (enExample)
IL (1) IL256186A (enExample)
MA (1) MA42249A (enExample)
MX (1) MX2017016337A (enExample)
WO (1) WO2016210275A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362384B (es) 2010-05-14 2019-01-15 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
US10124009B2 (en) 2014-10-27 2018-11-13 Tensha Therapeutics, Inc. Bromodomain inhibitors
WO2024123929A1 (en) * 2022-12-06 2024-06-13 Bioventures, Llc Development of potent dual hdac/brd4 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532130A (ja) * 2010-05-14 2013-08-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US8476260B2 (en) * 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US9102677B2 (en) 2009-11-05 2015-08-11 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MX2012005295A (es) 2009-11-05 2012-06-19 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina.
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MX362384B (es) * 2010-05-14 2019-01-15 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532130A (ja) * 2010-05-14 2013-08-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 15, no. 18, JPN6020017637, 2010, pages 3763 - 3771, ISSN: 0004275018 *

Also Published As

Publication number Publication date
HK1252062A1 (zh) 2019-05-10
CN107787227A (zh) 2018-03-09
BR112017028178A2 (en) 2018-08-28
IL256186A (en) 2018-02-28
WO2016210275A1 (en) 2016-12-29
KR20180035785A (ko) 2018-04-06
MA42249A (fr) 2018-05-02
AU2016283020A1 (en) 2018-01-04
EP3314005A1 (en) 2018-05-02
CA2989313A1 (en) 2016-12-29
AR105124A1 (es) 2017-09-06
MX2017016337A (es) 2018-11-22
US20180193350A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
JP2018520124A (ja) Ｎｕｔ正中線癌の治療
US7612206B2 (en) Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
Ory et al. PET radioligands for in vivo visualization of neuroinflammation
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
EA038337B1 (ru) Ингибиторы ezh2 для лечения лимфомы
CA3182373A1 (en) Composition for use in the treatment of apol1-associated disease
UA119538C2 (uk) Лікування злоякісної пухлини дигідропіразинопіразинами
WO2008115443A1 (en) Kinase protein binding inhibitors
AU2014361814A1 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
WO2016040527A1 (en) Metabolism probes for therapy and diagnosis
JP2009537626A (ja) ９−ヒドロキシエリプチシン誘導体による悪性表現型の復帰変異
TWI306401B (en) Benzothiazolium compounds
RS64936B1 (sr) Metodi lečenja hematoloških maligniteta korišćenjem 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benz il)amino-)izoindolin 1,3-diona
HUP0302496A2 (hu) Nempeptid bombezinreceptor-antagonisták felhasználása szorongás és pánikbetegség kezelésére
US20250170097A1 (en) Cathepsin inhibitors and use thereof in a method for detecting and treating resistance to immunotherapy
WO2024137506A1 (en) Compositions and methods for improving neurological diseases and disorders
WO2024137478A1 (en) Methods for treating various conditions and indications with agonists and antagonists
WO2026006503A9 (en) Compounds as nlrp3 pet radiotracers and compositions and uses thereof
CN116801875A (zh) 用于改善神经疾病和病症的组合物和方法
JP6280050B2 (ja) 肥満症予防又は治療剤，リウマチの予防又は治療剤
HK40053020A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
Mealy et al. Neurologic Drugs
HK1147417A (en) Kinase protein binding inhibitors
JP2012519697A (ja) キナーゼタンパク質結合阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210120